Work

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

Year: 2011

Type: article

Study design: Clinical Trial

Source: Urologic Oncology Seminars and Original Investigations

DOI: 10.1016/j.urolonc.2010.09.018

Authors: Young E. Whang, Andrew J. Armstrong, W. Kimryn Rathmell, Paul A. Godley, William Y. Kim, Raj S. Pruthi, Eric M. Wallen, Jeffrey M. Crane, Dominic T. Moore, Gayle Grigson, Karla Morris, Catharine P. Watkins, Daniel J. George

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Duke University, Duke Medical Center, Rex Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

OpenAlex ID: W2007699862

FWCI: 5.933

Cites: 34

Cited by: 89

Related to: 10